Challenge to ABO blood type barrier in living donor liver transplantation

ABO incompatible living donor liver transplantation has the potential to expand the donor pool for patients with end stage liver diseases on the expense of challenges to overcome immunological barriers across blood type.There is a profound impact of age on incidence and severity of antibody mediated rejection(AMR).Even children older than 1 year have chances of AMR;children aged 8 years or older have risks of hepatic necrosis similar to adult liver recipients.The mechanism of AMR is based on circulatory disturbances secondary to inflammation and injury of the vascular endothelium caused by an antibody-antigen-complement reaction.The strategy to overcome ABO blood type barrier is based on both pre-transplant desensitization and adequate treatment of this phenomenon.Nowadays,rituximab is the standard means of desensitization but unfortunately an insufficient aid to treat AMR.Because of low incidence(less than 5%in the rituximab era),in practice of AMR only some case reports about the treatment of clinical AMR are available in the literature.Initial experiences revealed that the proteasome inhibitor,bortezomib might be a promising treatment based on its capacity to deplete plasma cell agents.Although ABO blood type barrier has been counteracted in 95%of patients by applying“rituximab-desensitization”,many issues,such as prediction of high-risk patients of infection and AMR and secure treatment strategies for evoked AMR,remain to be resolved.

Prognostic role of the ABO blood types in Chinese patients with curatively resected non-small cell lung cancer:a retrospective analysis of 1601 cases at a single cancer center

Background:A positive association between the ABO blood types and survival has been suggested in several malignancies.The aim of this study was to assess the role of the ABO blood types in predicting the prognosis of Chinese patients with curatively resected non-small cell lung cancer(NSCLC).Methods:We retrospectively analyzed 1601 consecutive Chinese patients who underwent curative surgery for NSCLC between January 1,2005 and December 31,2009.The relationship between the ABO blood types and survival was investigated.In addition,univariate and multivariate analyses were performed.Results:Group 1(patients with the blood type O or B) had significantly prolonged overall survival(OS) compared with group 2(patients with the blood type A or AB),with a median OS of 74.9 months versus 61.5 months[hazard ratio(HR) 0.83;95%confidence interval(CI) 0.72-0.96;P = 0.015].Additionally,group 1 had significantly longer disease-free survival(DFS;HR 0.86;95%CI 0.76-0.98;P = 0.022) and locoregional relapse-free survival(LRFS;HR 0.79;95%CI 0.64-0.98;P = 0.024) than group 2.The association was not significantly modified by other risk factors for NSCLC,including smoking status,pathologic tumor-node-metastasis stage,pT category,pN category,and chemotherapy.Conclusions:There is an association between the ABO blood types and the survival of Chinese patients with resected NSCLC.Patients with the blood type O or B had significantly prolonged OS,DFS,and LRFS compared with those with the blood type A or AB.

ABO blood type is associated with endometrial cancer risk in Chinese women

ABO blood type has been associated with risk of several malignancies. However, results are not consistent. In this population-based case-control study including 1204 incident endometrial cancer cases and 1212 population controls, we examined the association of self-reported serologic blood type with endometrial cancer risk using a logistic regression model. Women with endometrial cancer were more likely to have blood type A. Compared to women with blood type O, the adjusted odds ratios for endometrial cancer were 1.00 [95% confidence interval (CI), 0.79-1.28] for type B, 1.24 (95% CI, 0.90-1.69) for type AB, and 1.50 (95% CI, 1.19-1.90) for type A. A significant dose-response relationship was observed for cancer risk and level of antigen A (P for trend = 0.0003). The positive association of blood type A with cancer risk was observed regardless of menopausal status, body mass index, oral contraceptive use, or family cancer history. Our results suggest that ABO blood type may be involved in the development of endometrial cancer.

ABO blood type, long-standing diabetes, and the risk of pancreatic cancer

AIM: To retrospectively study pancreatic cancer patients with respect to their ABO blood type and diabetes. METHODS: Our analysis included a cohort of 1017 patients with pancreatic ductal cancer diagnosed at our hospital in Tokyo. They were divided into two groups: 114 patients with long-standing type 2 diabetes (DM group, defined as diabetes lasting for at least three years before the diagnosis of pancreatic cancer) and 903 patients without diabetes (non-DM group). Multivariate analysis was performed to identify factors that are associated with long-standing diabetes. The DM group was further divided into three subgroups according to the duration of diabetes (3-5 years, 5.1-14.9 years, and 15 years or more) and univariate analyses were performed. RESULTS: Of the 883 pancreatic cancer patients with serologically assessed ABO blood type, 217 (24.6%) had blood type O. Compared with the non-DM group, the DM group had a higher frequency of blood type B [odds ratio (OR) = 2.61, 95%CI: 1.24-5.47; reference group: blood type A]. Moreover, male (OR = 3.17, 95%CI: 1.67-6.06), older than 70 years of age (OR = 2.19, 95%CI: 1.20-3.98) and presence of a family history of diabetes (OR = 6.21, 95%CI: 3.38-11.36) were associated with long-standing type 2 diabetes. The mean ages were 64.8 ± 9.2 years, 67.1 ± 9.8 years, and 71.7 ± 7.0 years in the subgroups with the duration of diabetes, 3-5 years, 5.1-14.9 years, and 15 years or more, respectively (P = 0.007). A comparison of ABO blood type distribution among the subgroups also showed a significant difference (P = 0.03). CONCLUSION: The association of pancreatic cancer with blood type and duration of diabetes needs to be further examined in prospective studies.

Prognostic role of ABO blood type in patients with extranodal natural killer/T cell lymphoma,nasal type:a triple.center study

Background:The prognostic significance of ABO blood type for lymphoma is largely unknown.We evaluated the prognostic role of ABO blood type in patients with extranodal natural killer(NK)/T-cell lymphoma(ENKTL).Methods:We retrospectively analyzed clinical data of 697 patients with newly diagnosed ENKTL from three cancer centers.The prognostic value of ABO blood type was evaluated using Kaplan-Meier curves and Cox proportional hazard models.The prognostic values of the International Prognostic Index(IPI) and the Korean Prognostic Index(KPI)were also evaluated.Results:Compared with patients with blood type O,those with blood type non-O tended to display elevated baseline serum C-reactive protein levels(P=0.038),lower rate of complete remission(P=0.005),shorter progression-free survival(PFS,P<0.001),and shorter overall survival(OS,P=0.001).Patients with blood type O/AB had longer PFS(P<0.001) and OS(P=0.001) compared with those with blood type A/B.Multivariate analysis demonstrated that age >60 years(P<0.001),mass ≥5 cm(P=0.001),stage Ⅲ/Ⅳ(P<0.001),elevated serum lactate dehydrogenase(LDH) levels(P=0.001),and blood type non-O were independent adverse predictors of OS(P=0.001).ABO blood type was found to be superior to both the IPI in discriminating patients with different outcomes in the IPI low-risk group and the KPI in distinguishing between the intermediate-to-low-and high-to-intermediate-risk groups.Conclusions:ABO blood type was an independent predictor of clinical outcome for patients with ENKTL.

Impact of ABO Blood Types on Survival after Pancreatectomy for Pancreatic Cancer

Background/Purpose: A recent genome-wide association study (PanScan) identified significant association between the ABO gene locus and the risk of pancreatic cancer. The aim of this study was to analyze survival of pancreatic cancer patients who underwent surgical resection based on serotype-defined ABO blood types. Methods: In terms of ABO blood types and gemcitabine-based adjuvant therapy, we investigated the survival of 153 patients who underwent pancreatectomy for pancreatic cancer at the Department of Surgery and Oncology,KyushuUniversity(Fukuoka,Japan). Results: Among the four blood type groups, the O serotype group (median survival time (MST): 47.9 months) showed the best prognostic outcome. The A serotype group (MST: 22.5 months) showed the second best prognostic outcome, followed by the AB serotype group (MST: 20.4 months). The B serotype group (MST: 15 months) showed the worst prognostic outcome when considering the MST after the surgical resection. Next, we examined the effect of adjuvant chemotherapy with gemcitabine based on the ABO blood types. The A serotype group showed the greatest improvement in prognosis by adjuvant therapy with gemcitabine after the surgical resection. The other three serotype groups showed no significant differences in the prognostic outcomes between subgroups with and without gemcitabine therapy. Conclusions: The present data suggest the possibility that ABO blood types are prognostic factors for pancreatic cancer patients after surgical treatment and are also predictive factors for the chemosensitivity to gemcitabine of pancreatic cancer patients after pancreatectomy.

质量监测指标在血站实验室ABO血型检测中的应用

目的分析ABO血型检测相关质量监测指标情况及其变化趋势,探讨质量监测指标在血站实验室ABO血型检测过程中的作用。方法以该中心2012—2021年2733642例献血者标本为研究对象,分析2012—2021年ABO血型检测过程中相关质量监测指标,包括特殊血型检出率、标本血型与血液制剂血型不一致率、采血部门血型检测错误率、送检血型与确认结果符合率等,对数据进行整理和分析。结果2012—2021年2733642例献血者特殊血型检出率中位数为0.030%,各年度比较,差异有统计学意义(0.019%~0.051%;χ^(2)=75.612,P<0.01)。标本血型与血液制剂血型不一致率为0.04■,各年度比较,差异有统计学意义(0.00■~0.21■;χ^(2)=15.787,P<0.01),呈递减趋势(χ^(2)=11.178,P<0.01)。采血部门血型检测错误率为0.55?,各年度比较,差异有统计学意义(0.24■~0.77■;χ^(2)=18.247,P<0.05),呈递减趋势(χ^(2)=8.143,P<0.01)。送检血型与确认结果符合率为78.24%,各年度比较,差异无统计学意义(70.94%~84.71%,χ^(2)=11.993,P>0.05),未见明显趋势变化(χ^(2)=0.879,P>0.05)。结论血站实验室应使用质量监测指标对ABO血型检测进行持续监控和过程评价,确保实验室检测能力的有效性、稳定性,为血型检测过程管理持续改进提供数据依据。

血清学检测和基因分型在ABO疑难血型鉴定中的性能评价

目的分析血清学检测和基因分型在ABO疑难血型鉴定中的应用。方法对106例ABO疑难血型实施血清学检测(吸收放散试验)等,同时对其实施基因分型检测(荧光定量PCR试验),以基因测序结果为金标准,评估血清学检测和基因分型所得结果与基因测序一致性,比较两种检查方式灵敏度、特异度。结果以基因测序为金标准,血清学检测所得结果一致性为中度,基因分型检测所得结果一致性很好。通过比较血清学检测和基因分型灵敏度、特异度可知,两种检查方式所得特异度、灵敏度差异有统计学意义,基因分型灵敏度、特异度更高(P<0.05)。结论基因分型检测和血清学检测有各自的优缺点,但总体上来说,基因分型检测具有更高的准确性和可靠性,更快速、高效。

The correlation between different ABO blood group gene loci and the pathogenesis and prognosis of acute myocardial infarction

Objective: To assess the effect of different ABO blood group gene locus on severity and prognosis of acute myocardial infarction (AMI). Methods: 100 patients with AMI diagnosed in our hospital from June 2018 to June 2019 were selected as the myocardial infarction group. At the same time, 100 healthy patients with physical examination results in our hospital were selected as the control group. Single-nucleotide polymorphisms of peripheral blood ABO gene loci rs505922, rs579459, rs643434, rs651007, and rs8176743 were detected. The differences of ABO blood group gene loci in different groups were compared. The correlation between the distribution of ABO blood group gene loci and the incidence and prognosis of patients with AMI was analyzed. Results: 98 cases were included in the myocardial infarction group and 99 cases were included in the control group. Compared with the control group, the genotypes of rs643434 and rs651007 locus in the myocardial infarction group were statistically significant (P<0.05). Analysis under different genetic models , compared with the control group, the myocardial infarction group had a significant difference in the rs643434 gene dominant mode, rs651007 dominant mode and recessive mode (P<0.05). The dominant mode of rs643434 was correlated with Gensini score and TIMI grade. The dominant mode of rs651007 was correlated with Gensini score, TIMI grade and troponin.The recessive mode of rs651007 was correlated with Gensini score, and the differences were statistically significant (P < 0.05). The dominant mode of rs643434 was related to the occurrence of MACE, and the difference was statistically significant (P < 0.05).Conclusion: Different genetic models of ABO blood group genes rs643434 and rs651007 may be related to the condition and prognosis of AMI.

广东潮汕地区恶性肿瘤与ABO血型的相关性分析

目的探讨ABO血型与广东潮汕地区恶性肿瘤发病风险的关系。方法采用卡方检验分析汕头大学医学院附属肿瘤医院45890例恶性肿瘤患者和汕头市中心血站42465例健康献血者中ABO血型分布差异。结果在各种主要类型恶性肿瘤中,食管癌和头颈部癌的ABO血型分布与正常人群分布存在差异,具有统计学意义(χ^(2)=11.16,P<0.05;χ^(2)=74.36,P<0.05)。B型人群为食管癌和头颈部癌高风险人群(OR=1.09,95%CI=1.03~1.15,P<0.05;OR=1.46,95%CI=1.34~1.60,P<0.05);A型和O型人群是头颈部癌低风险人群(OR=0.87,95%CI=0.79~0.96,P<0.05;OR=0.83,95%CI=0.76~0.90,P<0.05)。结论潮汕地区汉族人食管癌和头颈部癌患者ABO血型分布与正常人群可能存在差异,提示不同血型可能与食管癌和头颈部癌的发生存在关联。

江苏省启东地区肝癌患者ABO血型分布及其与肝癌发病风险的关系

目的了解江苏省启东地区肝癌患者ABO血型分布情况,探讨ABO血型与肝癌发病风险的关系。方法选择1701例启东籍肝癌患者、2828例排除疾病后的启东籍健康体检人员,采集两组外周静脉血检测ABO血型,分析ABO血型与肝癌发生风险的关系。结果1701例肝癌患者中,血型为A型者518例(30.45%)、B型者436例(25.63%)、O型者518例(30.45%)、AB型者229例(13.46%);2828例体检健康者中,血型为A型者862例(30.48%)、B型者818例(28.93%)、O型者853例(30.16%)、AB型者295例(10.43%),与健康人群比较,肝癌患者中AB型比例高、B型比例低(P均<0.05)。B型的启东籍人群发生肝癌的风险低(OR=0.847,95%CI:0.739~0.970),AB型启东籍人群发生肝癌的风险高(OR=1.336,95%CI 1.111~1.606)。与健康人群比较,男性肝癌患者B型比例低、AB型比例高(χ^(2)=5.618,11.01;OR分别为0.809,1.534;P均<0.05)。结论江苏省启东地区肝癌的发生与ABO血型有关,AB型人群发生肝癌的风险高,B型人群发生肝癌的风险低。

ABO血型对达比加群酯治疗非瓣膜性房颤效果的影响

目的分析ABO血型不同的非瓣膜性房颤患者应用新型口服抗凝药物达比加群酯治疗前后的凝血功能指标变化情况。方法选取100例非瓣膜性房颤患者作为研究对象,根据血型分为O型组(n=50)和非O型组(n=50),2组均给予达比加群酯胶囊治疗。比较2组患者3个月后凝血功能指标。结果治疗前,2组房颤患者血管性血友病因子(vWF)及蛋白C活性比较,差异有统计学意义(P<0.05);治疗后,2组房颤患者vWF及蛋白C活性比较,差异有统计学意义(P<0.05)。治疗前,2组活化部分凝血活酶时间(APTT)比较,差异无统计学意义(P>0.05),但治疗后2组APTT差异有统计学意义(P<0.05)。治疗前及治疗后,2组间血浆凝血酶原时间(PT)、凝血酶时间(TT)、国际标准化比值(INR)、凝血因子Ⅷ比较,差异均无统计学意义(P>0.05)。2组治疗后所有凝血相关指标与治疗前比较,差异均有统计学意义(P<0.05)。结论O型血患者应用达比加群酯治疗时更应警惕出血事件的发生,并一定程度上可通过APTT和蛋白C活性进行预测。

恩施土家族苗族地区患者ABO正反定型不符原因及分子生物学分析

目的探究恩施土家族苗族地区患者ABO正反定型不符原因及分子生物学分析结果。方法以2018年10月~2022年10月我院鉴定的59例ABO正反定型不符样本为研究对象进行回顾性研究。分别对样本进行吸收放散试验、意外抗体检测以及分子生物学检测,分析ABO正反定型不符原因,并对比血清学及分子生物学检测结果。结果59例ABO正反定型不符样本中正定型异常8(13.56%)例,反定型异常47(79.66%)例,正、反定型异常4(6.78%)例。男性比例62.71%(37/59)高于女性比例37.29%(22/59)(P<0.05);≥61岁年龄段比例42.37%(25/59)高于41~50岁年龄段比例32.20%(19/59)和51~60岁年龄段比例25.42%(15/59)(P<0.05)。17例ABO亚型样本中12(70.6%)例为土家族。59例正反定型不符样本中29(49.16%)例为意外抗体,17(28.81%)例为ABO亚型,13(22.03%)例为血清抗体减弱。17例ABO亚型中,A亚型6例(A2型1例,A3型4例,Ael型1例),B亚型4例(B3型3例,Bel型1例),AB3型2例,B亚型(A型)3例,cisAB型2例。17例ABO亚型中,有8例血清学结果与基因分型结果一致,一致率47.1%(8/17)。A亚型中以A 307/O 02基因型为主,B亚型中以B 303/O 02基因型为主。结论ABO亚型是恩施土家族苗族地区ABO正反定型不符的重要原因。亚型中A亚型以A307/O02基因型为主,B亚型以B 303/O02基因型为主。

ABO不同血型在不同保存期内CD38的表达

目的 探讨ABO不同血型、不同保存期内红细胞表面CD38的表达,以明确其对多发性骨髓瘤(multiple myeloma,MM)患者应用了达雷妥尤单抗后的血液选择问题。方法 选取2022年5月25日—2022年6月30日全军采供血中心采集的供者血液标本,A型、B型、O型、AB型四个血型自血液采集之日起分为5个保存周期,四个血型不同保存期内的正常标本各15个,共300个标本。每一个保存周期、不同血型随机5人份混匀后为一组,分为三组标本。将含量为100mg/5mL的CD38单抗注射液原液用生理盐水稀释,确定了CD38单抗浓度梯度。采用标准输血技术检测,将红细胞和不同含量的CD38抗体按比例(红细胞50μL、CD38抗体25μL)加入抗人球蛋白卡中,孵育15min,离心10min后观察结果。结果 A型、B型、O型、AB型四个血型,红细胞与CD38单抗凝集强度一致,差异无统计学意义(P>0.05)。CD38单抗浓度为256ng时与不同保存周期的红细胞均为2+凝集,差异无统计学意义(P=0.062)。CD38单抗浓度为128ng及64ng时五个保存周期的红细胞凝集有减弱,差异有统计学意义(P <0.05)。结论 ABO不同血型的CD38表达基本一致,无明显差异,不同保存期的红细胞对多发性骨髓瘤(MM)患者不会引起溶血的增加。

ABO血型vWF和凝血因子Ⅷ与血液透析患者AVF血栓首次形成的关系

目的探讨不同ABO血型血液透析患者血管性血友病因子抗原(vWF:Ag)水平和凝血因子Ⅷ活性变化与动静脉内瘘(AVF)血栓首次形成的关系。方法选取364例AVF血液透析患者为观察对象,检测其ABO血型,观察O型血患者和非O型血患者血管性血友病因子(vWF)、凝血因子Ⅷ水平和3个月内初次内瘘血栓发生率并进行比较。结果O型血患者和非O型血患者AVF血栓发生率分别为12.50%(14/112)和22.62%(57/252),差异具有统计学意义(P<0.05);O型血患者vWF:Ag水平和凝血因子Ⅷ活性分别为(125.98±32.79)%和(131.52±32.97)%,非O型血患者分别为(158.29±32.97)%和(147.10±36.61)%,两者差异具有统计学意义(P<0.05)。结论ABO血型与血液透析患者AVF血栓首次形成密切相关,非O型血AVF患者存在vWF:Ag水平和凝血因子Ⅷ活性表达明显增加,较O型血患者更容易形成内瘘血栓。

精准ABO血型鉴定与精准输血的价值研究

目的:研究精准ABO血型鉴定与精准输血的价值。方法:选取2017年11月—2019年10月新郑市人民医院需进行输血的患者132例,按照随机数表法分为试验组(n=66)与对照组(n=66),对照组采用常规ABO血型鉴定,试验组采用精准ABO血型鉴定。分析ABO血型在不同年龄段及不同性别分布特点,比较两组患者不规则抗体阳性与D抗体阳性率。结果:132例需输血患者中,A型血31例,占比23.48%(31/132),B型血28例,占比21.21%(28/132),O型血53例,占比40.15%(53/132),AB型血20例,占比15.15%(20/132);其中20~39岁、40~59岁、≥60岁年龄段中血型分布均为AB型<B型<A型<O型;医院132例需输血患者中,男性A型血、B型血、O型血、AB型血分别为17例(12.88%)、15例(11.36%)、28例(21.21%)、11例(8.33%),女性A型血、B型血、O型血、AB型血分别为14例(10.61%)、13例(9.85%)、25例(18.94%)、9例(6.82%),男性与女性血型分布均为AB型<B型<A型<O型;与对照组[12.12%(8/66)、13.64%(9/66)]相比,试验组不规则抗体阳性率[3.03%(2/66)]、D抗体阳性率[1.52%(1/66)]均较低,差异有统计学意义(χ^(2)=3.895、6.925,P<0.05)。结论:ABO血型在不同年龄段及性别中分布不同,对患者进行精准ABO血型鉴定可为临床精准输血提供依据,有助于临床匹配血型。

ABO疑难血型鉴定及正反定型不符原因分析

目的:分析ABO疑难血型鉴定及正反定型不符原因。方法:选取2021年1月—2023年5月厦门大学附属第一医院杏林分院92例ABO疑难血型血液标本。所有血液标本采用盐水试管法进行血型正反定型,并采用凝聚胺法、吸收放散试验对血型进行进一步检测。统计三种方法检测血型正反定型的符合率,并分析盐水试管法正反定型不符合的原因,完成ABO血型鉴定。结果:92例血液标本检测结果显示,盐水试管法、盐水试管法+凝聚胺法、盐水试管法+凝聚胺法+吸收放散试验检测血型正反定型符合率分别为44.57%(41/92)、51.09%(47/92)、77.17%(71/92)。盐水试管法正反定型不符合的主要原因为AB亚型、弱B抗原、弱A抗原、无抗-B抗体A型、无抗体O型。92例ABO疑难血型中,A亚型29例,B亚型50例,AB亚型13例。结论:临床通过盐水试管法+凝聚胺法+吸收放散试验对ABO疑难血型进行正反定型,可提高血型鉴定准确率。

探讨产前及输血前检测孕产妇ABO与RhD血型的临床意义

目的探讨产前及输血前检测孕产妇ABO与RhD血型的临床意义。方法选取80例进行体检的孕产妇,所有孕产妇均进行血型鉴定,并完成不规则抗体检测,观察其检验结果。结果80例孕产妇中,不规则抗体阳性有12例(15.00%),包括有妊娠史的孕产妇8例和输血史的孕产妇4例。12例不规则抗体阳性结果的孕产妇中A型血有3例(25.00%),B型血有3例(25.00%),O型血有5例(41.67%),AB型血有1例(8.33%)。其中,RhD阳性占11/12(91.67%),抗E占比最高,为5/12(41.67%),抗Ec占2/12(16.67%),抗D占2/12(16.67%),抗C占1/12(8.33%),抗c占1/12(8.33%)。结论在产前和输血前为孕产妇实施不规则抗体、ABO和RhO血型检测,可为临床上明确母婴血型的不匹配和易流产情况或新生儿溶血病等提供依据,以尽早加以筛查和处理,具有重要的检验指导性意义。

Ax22亚型导致家族性血型鉴定错误的研究

目的通过对ABO血型为Ax22/B型的患者及其家属因A亚型造成血清学血型鉴定错误的案例进行分析,总结ABO血型鉴定过程中的注意事项及A亚型的输血策略。方法分别选取A、B两种不同厂家的微柱凝胶血型鉴定卡及试管法在常温和4℃孵育10 min两种条件下对患者及其子女进行血清学血型鉴定;对所有标本进行吸收放散试验及血型基因鉴定;分别用微柱凝胶法和聚凝胺法对同一组标本进行交叉配血。结果B试剂卡凝集强度明显高于A试剂卡,且正定型B试剂卡可以在常温下检测到A抗原,A试剂卡仅在4℃孵育10 min后才可检测到A抗原。试管法血型可明确显示A亚型的反应格局。吸收放散试验显示所有标本红细胞表面均存在A抗原,经基因测序患者为Ax22/B.01,其子女基因型为Ax22/O.01.01。微柱凝胶法交叉配血相合,聚凝胺法镜下可见细胞凝集,交叉配血不合。结论Ax22会造成检测结果假阴性,如正反定型不一致或者对检测结果有任何疑问,应选用试管法或其他检测系统进行复核,必要时进行基因检测;Ax22亚型在配血时有假阴性的可能,有较高的输血风险。

ABO血型不合异基因造血干细胞移植受者血型检测与血液成分输注专家共识

目前ABO血型不合造血干细胞移植(HSCT)占整体HSCT的30%~50%,ABO血型不合已不是造血干细胞移植的主要障碍。输血治疗是HSCT患者移植过程的重要支持治疗,而正确的血型定型和血液成分的选择显得尤为重要。对于ABO血型不合的HSCT患者,在移植前、中、后不同时期应采用何种技术完成ABO血型检测并出具检验报告,如何选择血液成分同时兼顾输注安全与疗效,一直是困扰临床输血工作者的难点问题之一。本共识由国内输血医学和血液病学专家共同深入探讨后完成,提取7条推荐意见,旨在进一步规范、细化ABO血型不合HSCT患者血型检测和血液成分输注策略,为实现HSCT患者血型检测规范报告和血液成分精准输注、不断提高输血安全和输注疗效提供技术支撑。